• Contact Us
  • Media
  • Careers
    • Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003

    For more information visit www.strategiccollaboration.net.

    Because I promised my granddaughter more days like this.

    Our commitment starts here.
    Find. Fight. Follow.™

    Because better insights mean better decision-making.

    Our commitment starts here.
    Find. Fight. Follow.™

    Because their lives are in our hands.

    Our commitment starts here.
    Find. Fight. Follow.™

    $55.48
    -0.53
    NASDAQ | LNTH (Common Stock)

    Data provided by Nasdaq.
    Minimum 15 minutes delayed.

    Visit Investor Site

    For more than half a century, our diagnostic and therapeutic innovations have changed the way clinicians Find, Fight and Follow® disease. Today, we go further still—with the same sense of purpose and commitment to empowering healthcare professionals with life-changing science that helps improve outcomes and lives.

    Our History

    News & Media

    12/06/22

    Lantheus Holdings, Inc. Announces Pricing of Offering of $500 Million Convertible Senior Notes due 2027

    NORTH BILLERICA, Mass. , Dec. 06, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company” or “Lantheus”) (NASDAQ: LNTH), today announced the pricing of $500 million in aggregate principal amount of the Company’s convertible senior notes due 2027 (the “Notes”).

    Read More
    12/05/22

    Lantheus Holdings, Inc. Announces Proposed Offering of $500 Million Convertible Senior Notes due 2027

    NORTH BILLERICA, Mass. , Dec. 05, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company” or “Lantheus”) (NASDAQ: LNTH), today announced that it intends to offer, subject to market conditions and other factors, $500 million in aggregate principal amount of the Company’s convertible senior

    Read More
    11/29/22

    Lantheus Announces Appointment of Amanda Morgan as Senior Vice President, Commercial

    NORTH BILLERICA, Mass. , Nov. 29, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease,

    Read More
    11/28/22

    Lantheus Announces the Approval of DEFINITY® (Perflutren Lipid Microsphere) by China’s NMPA

    DEFINITY is the leading diagnostic ultrasound enhancing agent for patients with suboptimal echocardiograms NORTH BILLERICA, Mass. , Nov. 28, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics,

    Read More